FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Ropinirole Hydrochloride Extended Release (Requip XL) Tablets
Status: Discontinuation
»Therapeutic Categories: Neurology

Expand all

GlaxoSmithKline (New 06/28/2019)

Company Contact Information:
888-825-5249

Presentation Posting Date Related Information
4 mg (NDC 0007-4887-13) 06/28/2019 This product discontinuation is a business related decision. The anticipated date that GSK will cease distribution of REQUIP XL 4 mg is approximately November 2019. The anticipated date that GSK will cease distribution of REQUIP XL 6 mg is approximately April 2020. The anticipated date that GSK will cease distribution of REQUIP XL 8 mg is approximately February 2020. The anticipated date that GSK will cease distribution of REQUIP XL 12 mg is approximately April 2020.
6 mg (NDC 0007-4883-13) 06/28/2019 This product discontinuation is a business related decision. The anticipated date that GSK will cease distribution of REQUIP XL 4 mg is approximately November 2019. The anticipated date that GSK will cease distribution of REQUIP XL 6 mg is approximately April 2020. The anticipated date that GSK will cease distribution of REQUIP XL 8 mg is approximately February 2020. The anticipated date that GSK will cease distribution of REQUIP XL 12 mg is approximately April 2020.
8 mg (NDC 0007-4888-13) 06/28/2019 This product discontinuation is a business related decision. The anticipated date that GSK will cease distribution of REQUIP XL 4 mg is approximately November 2019. The anticipated date that GSK will cease distribution of REQUIP XL 6 mg is approximately April 2020. The anticipated date that GSK will cease distribution of REQUIP XL 8 mg is approximately February 2020. The anticipated date that GSK will cease distribution of REQUIP XL 12 mg is approximately April 2020.
12 mg (NDC 0007-4882-13) 06/28/2019 This product discontinuation is a business related decision. The anticipated date that GSK will cease distribution of REQUIP XL 4 mg is approximately November 2019. The anticipated date that GSK will cease distribution of REQUIP XL 6 mg is approximately April 2020. The anticipated date that GSK will cease distribution of REQUIP XL 8 mg is approximately February 2020. The anticipated date that GSK will cease distribution of REQUIP XL 12 mg is approximately April 2020.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English